Aptorum Group Limited (NASDAQ:APM) Sees Large Drop in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 62,491 shares, a drop of 38.5% from the June 15th total of 101,658 shares. Approximately 2.7% of the company’s stock are sold short. Based on an average trading volume of 42,111 shares, the short-interest ratio is presently 1.5 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Aptorum Group from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aptorum Group has an average rating of “Sell”.

Aptorum Group Trading Up 0.4%

Shares of Aptorum Group stock opened at $0.82 on Thursday. Aptorum Group has a 52 week low of $0.65 and a 52 week high of $4.47. The firm’s 50 day moving average is $0.86 and its two-hundred day moving average is $0.89.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.